Soligenix invited to NORD conference to present preliminary Dusquetide, RiVax results

Soligenix, Inc. was invited to the National Organization for Rare Disorders’ (NORD) Rare Diseases and Orphan Products Breakthrough Summit on Tuesday to present preliminary data on the Dusquetide and RiVax programs.

NORD’s Rare Diseases and Orphan Products Breakthrough Summit brings together presenters from the FDA, pharmaceutical and biotech industry experts, investment professionals and commercialization stakeholders.

Dusquetide and RiVax were granted orphan drug designation by the U.S. Food and Drug Administration (FDA), which designates drugs for the diagnosis, treatment or prevention of rare disorders that affect fewer than 200,000 people in the United States.

Dusquetide is designated for the treatment of macrophage activation syndrome (MAS). The treatment is a first-in-class innate defense regulator that modulates the response of the innate immune system in response to infection, tissue damage and inflammation. The treatment was developed through discoveries made by Dr. Brett Finlay and Dr. Robert Hancock, professors at the University of British Columbia in Canada.

RiVax is designated for the prevention of ricin intoxication. The proprietary vaccine candidate utilizes an antigen that is devoid of the toxic activity of ricin. RiVax is typically used with Soligenix’s ThermoVax, which enhances the treatment’s thermostability. The treatment was developed through a series of grants from the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, and the FDA, and originated at the University of Texas Southwestern.

Soligenix is a late-stage biopharmaceutical company that focuses on developing and commercializing treatments for rare diseases where there is an unmet medical need.